adenine has been researched along with cobicistat in 77 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 61 (79.22) | 24.3611 |
2020's | 16 (20.78) | 2.80 |
Authors | Studies |
---|---|
Chuck, SL; Cohen, C; DeJesus, E; Elion, R; Kearney, BP; Liu, HC; Ramanathan, S; Rashbaum, B; Ruane, P; Shamblaw, D; Warren, DR; Yale, K | 1 |
Chuck, SL; Cohen, C; Elion, R; Gathe, J; Hawkins, T; Kearney, BP; Liu, HC; Mathias, AA; Shalit, P; Warren, DR | 1 |
Cheng, AK; DeJesus, E; Gathe, J; Henry, K; Kearney, BP; Molina, JM; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X; White, K; Yale, K | 1 |
Cheng, AK; Cohen, C; DeJesus, E; Gallant, JE; Kearney, BP; Liu, HC; Mills, A; Quirk, E; Sax, PE; Szwarcberg, J; White, K; Wohl, D; Yale, K; Zhong, L; Zolopa, A | 1 |
Debyser, Z; Schrijvers, R | 2 |
Lepist, EI; Maclennan, K; Murray, B; Phan, TK; Ray, AS; Roy, A; Tong, L | 1 |
Pommer, P | 1 |
Belavic, JM | 1 |
Abram, M; Cheng, AK; DeJesus, E; Fordyce, MW; Gathe, J; Henry, K; Molina, JM; Plummer, A; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X | 1 |
Cahn, P; Sued, O | 1 |
Andrade-Villanueva, J; Antunes, F; Arastéh, K; Callebaut, C; Cheng, AK; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, Y; Moyle, G; Rhee, MS; Rizzardini, G; Szwarcberg, J; Zhong, L | 1 |
Bam, RA; Birkus, G; Cihlar, T; Hao, J; Lepist, EI; Ray, AS; Stray, KM; Yant, SR | 1 |
Aldir, I; Horta, A; Serrado, M | 1 |
Ikeda, A; Irie, S; Ishikawa, T; Kimura, M; Matsuki, S; Nishino, N; Shiomi, M | 1 |
Hsiao, CB; Ma, Q; Sawyer, JR | 1 |
Ayala-Sims, VA; Fulco, PP | 1 |
Antela, A; Domingo, P; Garner, W; Girard, PM; Guyer, B; Henry, K; Markowitz, M; Mills, A; Nguyen, T; Piontkowsky, D; Pozniak, A; Stellbrink, HJ; White, K | 1 |
Arribas, JR; Di Perri, G; Ebrahimi, R; Gathe, J; Nguyen, T; Pialoux, G; Piontkowsky, D; Reynes, J; Tebas, P; White, K | 1 |
Bruzzone, B; Di Biagio, A; Gustinetti, G; Prinapori, R; Sticchi, L; Taramasso, L; Viscoli, C | 1 |
Abram, ME; Andrade-Villanueva, JF; Beraud, C; Cheng, AK; Fisher, M; Graham, H; Liu, Y; Post, FA; Rhee, MS; Szwarcberg, J; Winston, J | 1 |
Baeten, JM; Wyatt, C | 1 |
Andrade-Villanueva, J; Callebaut, C; Cao, H; Cheng, AK; Crofoot, G; Custodio, JM; DeJesus, E; Fordyce, MW; Koenig, E; Martin, H; McCallister, S; Molina, JM; Oka, S; Plummer, A; Podzamczer, D; Post, F; Pozniak, A; Saag, M; Sax, PE; Thompson, M; Trottier, B; Wohl, D; Yin, MT; Zhong, L | 1 |
Abram, ME; Andrade-Villanueva, JF; Antunes, F; Arastéh, K; Cao, H; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, HC; Rizzardini, G; Szwarcberg, J | 1 |
Bam, RA; Birkus, G; Cihlar, T; Frey, CR; Stray, KM; Tsai, L; Willkom, M; Yant, SR | 1 |
Arribas, JR; Brinson, C; Brunetta, J; Callebaut, C; Cheng, A; Cheret, A; Clarke, A; Clumeck, N; Das, M; Fordyce, M; Mussini, C; Oka, S; Rashbaum, B; Sax, PE; Stephens, J; Tashima, K; Tebas, P; Wohl, D; Zhong, L | 1 |
Callebaut, C; Fordyce, M; Kitrinos, KM; Margot, NA; McCallister, S; Miller, MD | 1 |
Benson, P; Brinson, C; Brunetta, J; Cheng, A; Crofoot, G; Das, M; Fordyce, M; Gallant, J; Garner, W; McCallister, S; Mills, A; Oka, S | 1 |
Deeks, ED; Greig, SL | 1 |
Jones, R; Levy, JB; Milburn, J | 1 |
Batra, J; Chakraborty, R; Gaur, AH; Kizito, H; Kosalaraksa, P; Luesomboon, W; Myers, M; Porter, D; Prasitsueubsai, W; Quirk, E; Rakhmanina, N; Rassool, M; Rhee, MS; SenGupta, D; Shao, Y; Ting, L | 1 |
Callebaut, C; Cox, S; Das, M; Margot, N; McCallister, S; Miller, MD | 1 |
Ambrosioni, J; Miró, JM; Mosquera, MM | 1 |
Abbink, E; Burger, D; Colbers, A; Duisenberg-van Essenberg, M; Jongbloed-de Hoon, M; Kruijssen, M; van Crevel, R; Velthoven-Graafland, K | 1 |
Arribas, JR; Callebaut, C; Cheng, A; Clarke, AE; Das, M; DeJesus, E; Guo, S; Haas, B; McCallister, S; McDonald, C; Plummer, A; Sax, PE; Thompson, M; Wang, H; Wohl, DA | 1 |
Castagna, A; Chiappetta, S; Galli, L; Lazzarin, A; Nozza, S; Poli, A; Ripa, M; Rovelli, C; Spagnuolo, V; Tambussi, G | 1 |
Ikushima, I; Irie, S; Ishikawa, T; Nemoto, T; Ninomiya, N; Yamada, H | 1 |
Baldelli, S; Cattaneo, D; Clementi, E; Galli, M; Gervasoni, C; Giacomelli, A; Mazzali, C; Meraviglia, P; Milazzo, L; Minisci, D; Resnati, C; Rizzardini, G | 1 |
DeJesus, E; Haas, B; Liu, YP; Makadzange, T; Margot, N; McCallister, S; Mills, A; Ramgopal, MN; Segal-Maurer, S | 1 |
Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Kido, A; Kityo, C; Kulkarni, R; Squires, K | 1 |
Clotet, B; Negredo, E | 1 |
Castagna, A; Lazzarin, A; Spagnuolo, V | 1 |
Deeks, ED | 1 |
Álvarez, H; Díaz-Cambre, H; García-González, J; Llibre, JM; Mariño, A; Valcarce, N | 1 |
Domingo, P; Gutierrez, MDM; Mateo, MG; Vidal, F | 1 |
Baugh, B; Crauwels, HM; Hijzen, A; Opsomer, M; Van Landuyt, E; Vanveggel, S | 1 |
Bandera, A; Bozzi, G; Colella, E; Gori, A; Squillace, N | 1 |
Andreoni, M; Cerva, C; Maffongelli, G; Malagnino, V; Sarmati, L; Teti, E | 1 |
Cottrell, ML; Garcia, B; Imaz, A; Kashuba, ADM; Morenilla, S; Niubó, J; Perez, E; Podzamczer, D; Tiraboschi, JM | 1 |
Capetti, AF; Cossu, MV; Giacomet, V; Rizzardini, G; Zuccotti, G | 1 |
Brown, K; Cunningham, D; De Wit, S; Eron, JJ; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Petrovic, R; Post, FA; Pulido, F; Van Landuyt, E | 1 |
Kaplun, O; Psevdos, G | 1 |
Conway-Washington, C; Dinh, C; Fountain, J; Haaland, RE; Hall, L; Holder, A; Kelley, CF; Livermont, T; Lupo, LD; Martin, A | 1 |
Brown, K; DeJesus, E; Eron, JJ; Girard, PM; Huhn, GD; Lathouwers, E; Luo, D; Molina, JM; Nettles, RE; Orkin, C; Petrovic, R; Van Landuyt, E; Wong, EY | 1 |
Castagna, A; Gianotti, N | 1 |
Das, M; Haubrich, R; Maggiolo, F; Mateo-Garcia, MG; McNicholl, I; Molina, JM; Ong, E; Piontkowsky, D; Pulido, F; Raffi, F; Rizzardini, G; Shao, Y | 1 |
Hollenbeck, BL; Kishore, S; Lee, MSL; Padival, S | 1 |
Ajana, F; Bani-Sadr, F; Bouvet, E; Cotte, L; Galempoix, JM; Gantner, P; Hessamfar, M; Hustache-Mathieu, L; Lebrette, MG; Muret, P; Pellissier, G; Piroth, L; Rey, D; Rouveix, E; Simon, A; Souala, MF; Truchetet, F; Valin, N | 1 |
Eron, JJ; Esser, S; Hufkens, V; Jezorwski, J; Lathouwers, E; Opsomer, M; Orkin, C; Podzamczer, D; Rockstroh, J; Van Landuyt, E; Vandekerckhove, L | 1 |
Benson, C; Bolan, R; Crofoot, G; Dunn, K; Gathe, J; Huhn, GD; Luo, D; Nettles, RE; Ramgopal, M; Simonson, RB | 1 |
Chuang, YC; Hung, CC; Kuo, PH; Liu, WC; Sun, HY; Wu, PY | 1 |
Castagna, A; Comi, L; Di Filippo, E; Fumagalli, L; Galli, L; Gianotti, N; Maggiolo, F; Nozza, S; Rizzi, M; Valenti, D | 1 |
Duan, Y; Zhou, C; Zhu, HL | 1 |
Chang, SF; Chang, SY; Chen, GJ; Cheng, CY; Chuang, YC; Hsieh, MH; Huang, SH; Hung, CC; Lee, CH; Lee, YC; Lee, YL; Su, LS; Sun, HY; Tang, HJ; Tsai, HC | 1 |
Barr, E; Best, BM; Brooks, KM; Capparelli, EV; Chakhtoura, N; Cielo, M; Denson, K; Deville, JG; Espina, R; Febo, IL; George, K; Haubrich, R; Mirochnick, M; Momper, JD; Pinilla, M; Rooney, JF; Rungruengthanakit, K; Shapiro, DE; Smith, E; Stek, AM; Weinberg, A | 1 |
Ma, R; Tong, ZW; Xu, B; Zhang, Q; Zhang, YS; Zhao, CS; Zhao, RG | 1 |
Benet, LZ; Gandhi, M; Koss, CA; Kuncze, K; Louie, A; Okochi, H; Phung, N; Spinelli, MA; Tallerico, RM; Zhang, K | 1 |
Gao, LY; Hu, Y; Huang, XJ; Ma, P; Wu, H; Wu, Y; Xia, H; Yan, ZF | 1 |
Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y | 1 |
Abdul Massih, S; Andrade, A; Beselman, S; Breakey, J; Fuchs, EJ; Hendrix, CW; Marzinke, MA; McNicholl, I | 1 |
Daharwal, SJ; Singh, VD; Singh, VK | 1 |
Ardila, F; Bernal, E; Casadellà, M; Curran, A; Echeverria, P; Estrada, V; Fanciulli, C; Gutierrez, A; Hernández, C; Hidalgo-Tenorio, C; Imaz, A; Knobel, H; Lagarde, M; Lopez-Lirola, A; Macias, J; Masiá, M; Montero-Alonso, M; Morano, L; Navarro-Alcaraz, A; Parera, M; Podzamczer, D; Portilla, J; Prieto, P; Rigo, R; Rivero, A; Troya, J; Valencia, E; Vivancos, MJ | 1 |
Isoda, A; Matsumoto, M; Mihara, M; Sawamura, M | 1 |
10 review(s) available for adenine and cobicistat
Article | Year |
---|---|
Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cobicistat; Deoxycytidine; Drug Combinations; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2012 |
Single-tablet regimens in HIV: does it really make a difference?
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tablets; Tenofovir; Thiazoles | 2014 |
Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Patents as Topic; Phosphorous Acids; Quinolones; Thiazoles | 2014 |
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Adolescent; Adult; Alanine; Anti-HIV Agents; Clinical Trials, Phase III as Topic; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir | 2017 |
Darunavir for the treatment of HIV infection.
Topics: Adenine; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Therapy, Combination; Emtricitabine; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Tenofovir; Treatment Outcome | 2018 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Genes, MDR; HIV Infections; HIV-1; Humans; Renal Reabsorption; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2018 |
Tolerability of Current Antiretroviral Single-Tablet Regimens
Topics: Adenine; Alanine; Anti-Retroviral Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir | 2018 |
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Protease Inhibitors; Randomized Controlled Trials as Topic; Tenofovir | 2018 |
An evaluation of elvitegravir plus cobicistat plus tenofovir alafenamide plus emtricitabine as a single-tablet regimen for the treatment of HIV in children and adolescents.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Child; Cobicistat; Emtricitabine; HIV Infections; Humans; Quinolones; Tablets; Tenofovir; United States; United States Food and Drug Administration | 2019 |
30 trial(s) available for adenine and cobicistat
Article | Year |
---|---|
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cobicistat; Cyclopropanes; Deoxycytidine; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Organophosphonates; Patient Compliance; Patient Selection; Quinolones; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; Tenofovir; Thiazoles | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2012 |
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Atazanavir Sulfate; Bilirubin; Bone Density; Carbamates; Cobicistat; Confidence Intervals; Creatinine; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Triglycerides | 2013 |
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2013 |
Effects of a protein-rich drink or a standard meal on the pharmacokinetics of elvitegravir, cobicistat, emtricitabine and tenofovir in healthy Japanese male subjects: a randomized, three-way crossover study.
Topics: Adenine; Adult; Anti-HIV Agents; Asian People; Beverages; Carbamates; Cobicistat; Cross-Over Studies; Deoxycytidine; Dietary Proteins; Drug Combinations; Emtricitabine; Food-Drug Interactions; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Tenofovir; Thiazoles; Young Adult | 2014 |
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Reverse Transcriptase Inhibitors; Tenofovir; Thiazoles; Viral Load | 2014 |
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results o
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Quinolones; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2014 |
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; Headache; HIV Infections; Humans; Kidney; Male; Nausea; Organophosphonates; Quinolones; Respiration Disorders; Sleep Initiation and Maintenance Disorders; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2015 |
Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Viral Load | 2015 |
Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
Topics: Adenine; Alanine; Albuminuria; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Proteinuria; Quinolones; RNA, Viral; Tenofovir | 2016 |
Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Cobicistat; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tenofovir; Young Adult | 2016 |
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Coinfection; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Male; Middle Aged; Quinolones; Tenofovir; Treatment Outcome | 2016 |
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.
Topics: Adenine; Adolescent; Alanine; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Child; Cobicistat; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lost to Follow-Up; Male; Quinolones; RNA, Viral; South Africa; Tablets; Tenofovir; Thailand; Uganda; United States; Viral Load | 2016 |
Brief Report: Pharmacokinetics of Crushed Elvitegravir Combination Tablet Given With or Without Enteral Nutrition.
Topics: Adenine; Adult; Anti-HIV Agents; Cobicistat; Cross-Over Studies; Emtricitabine; Enteral Nutrition; Female; Healthy Volunteers; Humans; Male; Middle Aged; Phosphorous Acids; Quinolones; Tablets; Young Adult | 2017 |
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
Topics: Adenine; Alanine; Anti-HIV Agents; Bone Density; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Emtricitabine; HIV Infections; Humans; Middle Aged; Quinolones; Tenofovir; Treatment Outcome; United States | 2017 |
Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects.
Topics: Adenine; Administration, Oral; Adult; Alanine; Anti-HIV Agents; Asian People; Breakfast; Cobicistat; Cross-Over Studies; Dietary Proteins; Dietary Supplements; Emtricitabine; Fasting; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Quinolones; Tenofovir | 2018 |
Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
Topics: Adenine; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Cobicistat; Drug Combinations; Drug Substitution; Emtricitabine; HIV Infections; HIV-1; Humans; Kidney; Quinolones; RNA, Viral; Tenofovir; Treatment Outcome | 2018 |
Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Integrase Inhibitors; Protease Inhibitors; Quinolones; RNA, Viral; Tenofovir | 2018 |
Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability.
Topics: Adenine; Adult; Alanine; Area Under Curve; Biological Availability; Cobicistat; Cross-Over Studies; Darunavir; Drug Combinations; Fasting; Female; Food; Humans; Male; Middle Aged; Tablets; Tenofovir; Therapeutic Equivalency; Young Adult | 2019 |
Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Topics: Adenine; Adult; Alanine; Anti-Retroviral Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolones; RNA, Viral; Semen; Semen Analysis; Tenofovir | 2019 |
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Darunavir; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Protease Inhibitors; Sustained Virologic Response; Tablets; Tenofovir; Viral Load; Young Adult | 2019 |
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a m
Topics: Adenine; Aged; Aged, 80 and over; Alanine; Anti-HIV Agents; Bone Density; Cobicistat; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Tablets; Tenofovir | 2019 |
Elvitegravir-Cobicistat-Emtricitabine-Tenofovir Alafenamide Single-tablet Regimen for Human Immunodeficiency Virus Postexposure Prophylaxis.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; HIV-1; Humans; Quinolones; Tablets; Tenofovir | 2020 |
Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Protease Inhibitors; Tablets; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBE 2).
Topics: Adenine; Anti-HIV Agents; Cobicistat; Darunavir; Emtricitabine; HIV Infections; HIV-1; Humans; Pharmaceutical Preparations; Rilpivirine; Treatment Outcome; Viral Load | 2020 |
EVG/COBI/FTC/TAF Bioequivalence Comparing Whole Tablets with Tablets Dissolved in Tap Water.
Topics: Adenine; Adult; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Tablets; Tenofovir; Therapeutic Equivalency | 2023 |
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Cobicistat; Darunavir; DNA; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Tandem Mass Spectrometry | 2023 |
37 other study(ies) available for adenine and cobicistat
Article | Year |
---|---|
Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro.
Topics: Adenine; Alanine; Caco-2 Cells; Carbamates; Cobicistat; HIV Protease Inhibitors; Humans; Intestinal Absorption; Tenofovir; Thiazoles | 2012 |
[A single tablet against HIV: new combination preparation improves therapy].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Glomerular Filtration Rate; HIV Infections; Humans; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2012 |
FDA approves new 4-drug once-a-day HIV treatment.
Topics: Adenine; Carbamates; Cobicistat; Deoxycytidine; Drug Administration Schedule; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles; United States; United States Food and Drug Administration | 2012 |
A 4-drug combination (Stribild) for HIV.
Topics: Adenine; Anti-HIV Agents; Carbamates; Clinical Trials as Topic; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Approval; Drug Combinations; Drug Interactions; Drug Resistance, Multiple, Viral; Emtricitabine; HIV; HIV Infections; Humans; Organophosphonates; Quinolones; Randomized Controlled Trials as Topic; Tenofovir; Thiazoles; United States; United States Food and Drug Administration | 2012 |
Drug updates and approvals: 2012 in review.
Topics: Acetanilides; Adenine; Antibodies, Monoclonal, Humanized; Benzazepines; Carbamates; Cobicistat; Deoxycytidine; Drug Approval; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Fatty Alcohols; Humans; Mifepristone; Nicotinic Acids; Nurse Practitioners; Organophosphonates; Phosphatidylglycerols; Prednisone; Proteins; Pyrimidines; Quinolones; Ranibizumab; Tenofovir; Thiazoles; United States; United States Food and Drug Administration | 2013 |
Boosting HIV treatment options: good news, new challenges.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles | 2013 |
Evaluation of the effect of cobicistat on the in vitro renal transport and cytotoxicity potential of tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cell Line; Cobicistat; Drug Interactions; Humans; In Vitro Techniques; Kidney; Male; Multidrug Resistance-Associated Proteins; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Organic Cation Transporter 2; Organophosphonates; Tenofovir; Thiazoles | 2013 |
[ First integrase inhibitor based single tablet regimen].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Drug Approval; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles; Treatment Outcome | 2013 |
Cobicistat + elvitegravir + emtricitabine + tenofovir. Two new drugs, but no progress.
Topics: Acquired Immunodeficiency Syndrome; Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV-1; Humans; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2013 |
Single-tablet, once-daily treatment regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cobicistat; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Drug Combinations; Emtricitabine; HIV Infections; HIV Integrase Inhibitors; HIV Reverse Transcriptase; Humans; Nitriles; Organophosphonates; Pyrimidines; Quinolones; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Thiazoles | 2014 |
Sustained virological response after taking crushed elvitegravir-cobicistat-emtricitabine-tenofovir tablets.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Organophosphonates; Powders; Quinolones; Tablets; Tenofovir; Thiazoles; Viral Load | 2014 |
Switching STRATEGIES in HIV treatment.
Topics: Adenine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Male; Organophosphonates; Protease Inhibitors; Quinolones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thiazoles | 2014 |
Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-infected patients with mild-to-moderate renal impairment.
Topics: Adenine; Adult; Anti-HIV Agents; Carbamates; Cobicistat; Cohort Studies; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Organophosphonates; Quinolones; Renal Insufficiency; Tenofovir; Thiazoles; Treatment Outcome | 2015 |
Tenofovir alafenamide for HIV infection: is less more?
Topics: Adenine; Alanine; Anti-HIV Agents; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Male; Organophosphonates; Quinolones; Tenofovir; Thiazoles | 2015 |
Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors.
Topics: Adenine; Alanine; Anti-HIV Agents; Biotransformation; Carboxylic Ester Hydrolases; Cathepsin A; CD4-Positive T-Lymphocytes; Cobicistat; Drug Interactions; Gene Expression; HEK293 Cells; HeLa Cells; HIV-1; Host-Pathogen Interactions; Humans; Oligopeptides; Primary Cell Culture; Prodrugs; Proline; RNA, Small Interfering; Serine Proteinase Inhibitors; Tenofovir | 2016 |
Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Organophosphates; Phenotype; Tenofovir | 2017 |
Comment on: Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection.
Topics: Adenine; Anti-HIV Agents; Cobicistat; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir | 2017 |
Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection-authors' response.
Topics: Adenine; Anti-HIV Agents; Cobicistat; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Organophosphonates; Quinolones; Tenofovir | 2017 |
Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.
Topics: Adenine; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxazines; Piperazines; Proportional Hazards Models; Pyridones; Quinolones; Raltegravir Potassium; Ritonavir; Tenofovir; Treatment Outcome | 2018 |
Efficacy of single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide in the treatment of HIV-1.
Topics: Adenine; Alanine; Anti-HIV Agents; Clinical Trials as Topic; Cobicistat; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Kidney Diseases; Tablets; Tenofovir | 2018 |
Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Overdose; Emtricitabine; HIV Infections; Humans; Male; Middle Aged; Quinolones; Renal Insufficiency; Suicide, Attempted; Tenofovir | 2019 |
Abnormal elevation of international normalized ratio in a patient during the coadministration of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and warfarin: a case report.
Topics: Adenine; Alanine; Cobicistat; Emtricitabine; HIV Infections; Humans; International Normalized Ratio; Quinolones; Tenofovir; Warfarin | 2019 |
Sustained HIV virologic suppression with crushed combination tablets containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Therapy, Combination; Emtricitabine; Enteral Nutrition; Gastrostomy; HIV Infections; HIV-1; Humans; Male; Middle Aged; Quinolones; Sustained Virologic Response; Tablets; Tenofovir | 2019 |
Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Topics: Adenine; Administration, Oral; Adolescent; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers; Cobicistat; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Quinolones; Sexual and Gender Minorities; Tenofovir; Time Factors; Young Adult | 2019 |
Switching antiretrovirals in older patients.
Topics: Adenine; Aged; Alanine; Bone Density; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Middle Aged; Quinolones; Tablets; Tenofovir | 2019 |
Fevers and Night Sweats in a 35-year-old Man With Recent Travel to Southeast Asia.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Asia, Southeastern; Cobicistat; Emtricitabine; HIV Infections; Humans; Laos; Male; Quinolones; Sweating; Tenofovir; Thailand; Travel; United States | 2019 |
Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Rapid-Initiation Model of Care for Human Immunodeficiency Virus Type 1 Infection: Primary Analysis of the DIAMOND Study.
Topics: Adenine; Adolescent; Adult; Aged; Alanine; Anti-HIV Agents; Cobicistat; Darunavir; Diamond; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Young Adult | 2020 |
Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cobicistat; Dyslipidemias; Emtricitabine; Female; HIV Seropositivity; Humans; Lipids; Male; Middle Aged; Quinolones; Retrospective Studies; Tenofovir; Weight Gain | 2020 |
Advance of promising targets and agents against COVID-19 in China.
Topics: Adenine; Adenosine Monophosphate; Alanine; Amides; Antimalarials; Antiviral Agents; Betacoronavirus; China; Chloroquine; Clinical Trials as Topic; Cobicistat; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cysteine Endopeptidases; Dibenzothiepins; Drug Combinations; Drug Discovery; Drug Therapy, Combination; Emtricitabine; Humans; Hydroxychloroquine; Indoles; Lopinavir; Medicine, Chinese Traditional; Morpholines; Oseltamivir; Oxazines; Pandemics; Pneumonia, Viral; Pyrazines; Pyridines; Pyridones; Ritonavir; RNA-Dependent RNA Polymerase; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Tenofovir; Thiepins; Triazines; Viral Nonstructural Proteins | 2020 |
Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; HIV Infections; HIV-1; Humans; Mutation; Quinolones; Retrospective Studies; Tenofovir | 2020 |
Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cobicistat; Emtricitabine; Female; HIV Infections; Humans; Postpartum Period; Pregnancy; Prospective Studies; Tenofovir | 2021 |
Preoperative rapid suppression of viral load by elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide regimen in human immunodeficiency virus-positive fracture patients significantly reduces postoperative complications.
Topics: Adenine; Alanine; Anti-HIV Agents; Cobicistat; Drug Combinations; Emtricitabine; HIV; HIV Infections; Humans; Postoperative Complications; Quinolones; Tenofovir; Viral Load | 2020 |
Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
Topics: Adenine; Anti-HIV Agents; Chromatography, High Pressure Liquid; Cobicistat; Dose-Response Relationship, Drug; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Hair; Hair Analysis; HIV Infections; Humans; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Tissue Distribution | 2021 |
Switching from efavirenz to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide reduces central nervous system symptoms in people living with HIV.
Topics: Adenine; Adult; Alanine; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cobicistat; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Male; Prospective Studies; Quality of Life; Quinolones; Sleep Quality; Tenofovir | 2021 |
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir | 2022 |
Utilization of Chemometric-Aided UV Spectrophotometric Methods for Concurrent Assessment of Emtricitabine, Tenofovir Disoproxil Fumarate, Elvitegravir, and Cobicistat in Tablet Formulation.
Topics: Adenine; Anti-HIV Agents; Chemometrics; Cobicistat; Drug Combinations; Emtricitabine; HIV Infections; Humans; Tablets; Tenofovir | 2023 |
Severe lactic acidosis during tenofovir disoproxil fumarate and cobicistat combination for HIV patient.
Topics: Acidosis, Lactic; Adenine; Anti-HIV Agents; Cobicistat; Drug Combinations; Female; HIV Infections; Humans; Middle Aged; Tenofovir; Thinness; Treatment Outcome | 2023 |